Molecular typing for blood group antigens within 40 min by direct polymerase chain reaction from plasma or serum

Influence of ABO blood group on susceptibility to different pathological types of lung cancer: a retrospective study

Purpose

Current research has shown a link between ABO blood group and many diseases. The purpose of this study aimed to investigate the influence of the ABO blood group on the risk of developing different pathological types of lung cancer.

Materials and methods

This retrospective study was composed of 7681 patients with lung cancer and 12, 671 non-lung cancer patients who were admitted to the First Affiliated Hospital of Nanchang University from January 2016 to January 2021. The subjects with lung cancer were grouped into small cell lung cancer group (n = 725), lung adenocarcinoma group (n = 4520), and lung squamous cell carcinoma group (n = 2286) according to pathological types. The ABO blood group distribution of each lung cancer type group was compared with that of the control group. Statistical analysis was determined with chi-square and logistic regression.

Results

Univariate analysis showed that the ABO blood group distribution of lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer was different from that of the control group (P < 0.01). After adjusting for age, sex, smoking history, and drinking history, logistic regression analysis showed that the risk of lung adenocarcinoma in blood type O was higher than that in blood type A (P < 0.01). There was no significant difference in ABO blood group composition between small cell lung cancer group, lung squamous cell carcinoma group, and control group (P > 0.05). In addition, gender and age have an influence on all three types of lung cancer (P < 0.01). Smoking was a risk factor in lung squamous cell carcinoma and small cell carcinoma (P < 0.01). Alcohol consumption was a risk factor in lung adenocarcinoma (P < 0.01).

Conclusion

ABO blood group may be correlated with the occurrence of lung adenocarcinoma in Jiangxi province, but not with lung squamous cell carcinoma and small cell carcinoma.

ABO blood classification and the risk of lung cancer: A meta‑analysis and trial sequential analysis

Patients with certain ABO classifications are at increased risk of certain types of malignancies. In the present study, a meta-analysis was performed to explore the association between the ABO blood group and the risk of lung cancer from an evidence-based medical perspective. The PubMed, Embase, Web of Science, Medline, China National Knowledge Infrastructure, Google Scholar, Science Direct and Wanfang databases were searched for relevant papers. Review Manger 5.4 was used to analyze the association between the ABO blood group and the risk of lung cancer. Trial Sequential Analysis (TSA) was used to determine whether the sample size of the meta-analysis was sufficient. A total of 29 studies were included in this paper. The results of the case-controlled studies showed that the proportion of patients with blood type A in patients with lung cancer was significantly higher than that in healthy individuals [odds ratio (OR), 1.10; 95% confidence interval (CI), 1.02-1.19]. Based on the subgroup analysis, type A blood showed heterogeneity in ethnicity and source of control (social or hospital). Additionally, type O blood was determined to be a protective factor for lung cancer in Caucasians (OR, 0.92; 95% CI, 0.85-0.99). TSA results suggested that there were sufficient participants in the case-controlled studies. Overall, the results of the cohort studies showed that the risk of lung cancer and blood type were weakly associated, and that the difference was not statistically significant. The case-controlled studies suggested that blood type A was associated with a higher risk of lung cancer. In addition, the analysis confirmed that Caucasians with type O blood had a lower risk of lung cancer. However, prospective cohort studies have not been able to draw this conclusion. Different experimental designs may have had a notable influence on the results obtained.

Duffy blood group system - the frequency of Duffy antigen polymorphisms and novel mutations in the Polish population

Duffy blood group genes are highly polymorphic with the distribution of alleles varying between different populations and ethnic groups. The aim of this study was to genotype Duffy blood group antigens and to establish FY alleles frequency in the Polish population and screen for novel FY gene mutations. Duffy phenotype and genotype frequencies analysis was based on studies of 596 persons. All these subjects were genotyped by high-resolution melting (HRM) method. It was shown that phenotype Fy(a+b+), defined by genotypes FY*A/FY*B (33%), FY*A/FY*B298A (13%), and FY*A/FY*02W.01 (2.8%) was the most common in Polish population (˜49%), followed by Fy(a-b+), ˜29%, determined by genotypes arising from FY*B allele and all its variants. Fy(a+b-) phenotype occurred with a frequency of 21.3% and was defined by the following genotypes: FY*A/A (21%), and FY*A/02N.01 (0.3%). Among the Polish population the frequencies of FY*A, FY*B, and FY*B298A alleles were 45.7%, 36% and 15.5%, respectively. The alleles FY*B298A and FY*B combined together, represented higher frequency (51%) than FY*A. Alleles FY*02W.01 and FY*02N.01 had frequencies 2.51% and 0.25%, respectively. The distribution of Duffy genotypes in the Polish population was in accordance with Hardy-Weinberg equilibrium (p = 0.9682). Alleles in the genotypes are independent from each other (r = 0.0278, R² = 0.00077). New mutations identified in the promoter region (c.-79T > C) and the coding region of the FY gene (c.147C > A and c.175 G > A) did not affect the Duffy antigen expression on erythrocyte. Although FY alleles frequency is known in different populations, no data for Polish population is available.

Genotyping of Single Nucleotide Polymorphisms Using Allele-Specific qPCR Producing Amplicons of Small Sizes Directly from Crude Serum Isolated from Capillary Blood by a Hand-Powered Paper Centrifuge

The cell-free genomic DNA (gDNA) concentration in serum ranges from 1500 to 7500 copies/mL within 2 h after phlebotomy (6⁻24 times the concentration observed in plasma). Here, we aimed to evaluate the gDNA size distribution in serum with time after coagulation and to test if crude serum can be directly used as a source of gDNA for qPCR. Next, we investigated if single nucleotide polymorphisms (SNPs) could be genotyped directly from the crude serum isolated from capillary blood using a hand-powered paper centrifuge. All tested PCR targets (65, 100, 202 and 688 base pairs) could be successfully amplified from DNA extracted from serum, irrespective of their amplicon size. The observed qPCR quantitation cycles suggested that the genomic DNA yield increased in serum with incubation at room temperature. Additionally, only 65 and 101 base pair qPCR targets could be amplified from crude serum soon after the coagulation. Incubation for 4 days at room temperature was necessary for the amplification of PCR targets of 202 base pairs. The 688 base pair qPCR target could not be amplified from serum directly. Lastly, serum was successfully separated from capillary blood using the proposed paper centrifuge and the genotypes were assigned by testing the crude serum using allele-specific qPCR, producing small amplicon sizes in complete agreement with the genotypes assigned by testing the DNA extracted from whole blood. The serum can be used directly as the template in qPCR for SNP genotyping, especially if small amplicon sizes are applied. This shortcut in the SNP genotyping process could further molecular point-of-care diagnostics due to elimination of the DNA extraction step.

Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype

Approximately 0·2-1% of routine RhD blood typings result in a "serological weak D phenotype." For more than 50 years, serological weak D phenotypes have been managed by policies to protect RhD-negative women of child-bearing potential from exposure to weak D antigens. Typically, blood donors with a serological weak D phenotype have been managed as RhD-positive, in contrast to transfusion recipients and pregnant women, who have been managed as RhD-negative. Most serological weak D phenotypes in Caucasians express molecularly defined weak D types 1, 2 or 3 and can be managed safely as RhD-positive, eliminating unnecessary injections of Rh immune globulin and conserving limited supplies of RhD-negative RBCs. If laboratories in the UK, Ireland and other European countries validated the use of potent anti-D reagents to result in weak D types 1, 2 and 3 typing initially as RhD-positive, such laboratory results would not require further testing. When serological weak D phenotypes are detected, laboratories should complete RhD testing by determining RHD genotypes (internally or by referral). Individuals with a serological weak D phenotype should be managed as RhD-positive or RhD-negative, according to their RHD genotype.